AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca emerging Markets excluding China — Revenue YoY at constant exchange rates / CER (%) (%)
Form 6-K Quarterly & Form 20-F Regional Revenue Table
Latest, Q2 2026
11.0%
Period ended Jun 30, 2026
Change on a year earlier
-10.0 pts
21.0% in Q2 2025
History
20 quarters
Since Q4 2020
Sources
20
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emerging Markets excluding China — Revenue YoY at constant exchange rates / CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 11.0% | -10.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 9.0% | -8.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 24.0% | -18.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 25.0% | -6.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 21.0% | +3.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 17.0% | -23.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 42.0% | +40.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 31.0% | +6.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 18.0% | -14.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 40.0% | – | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 2.0% | +31.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 25.0% | +40.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 32.0% | +25.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -29.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | -15.0% | -127.0 pts | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | 7.0% | -56.0 pts | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q3 2021 | Sep 30, 2021 | 112.0% | – | Form 6-K FY2021Q3 Earnings Release ↗ |
| Q2 2021 | Jun 30, 2021 | 63.0% | – | Form 6-K FY2021Q2 Earnings Release ↗ |
| Q1 2021 | Mar 31, 2021 | 11.0% | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | 7.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Emerging Markets excluding China — Revenue YoY at constant exchange rates / CER (%) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/rev_reg_em_ex_china_cer_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.